EUVIMEDEUVIMED entdecken
Open Access

PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections

Ryan M Shepard iD, Anghesom Ghebremedhin iD, Isaraphorn Pratumchai iD, Sally R Robinson iD, Courtney Betts, Jingjing Hu, Roman Sasik iD, Kathleen M Fisch iD, Jaroslav Zak iD, Hui Chen, Marc Paradise, Jason Rivera und 30 weitere

Science Translational Medicine · 03.07.2024 · 16 (754)

DOI: 10.1126/scitranslmed.adi6887 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, erschienen am 03.07.2024. Verfasst von Ryan M Shepard und 41 weiteren Autor:innen. Beteiligte Einrichtung: Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: Class Ib Phosphatidylinositol 3-Kinase, COVID-19, Inflammation, SARS-CoV-2. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIDCR NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Virulent infectious agents such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and methicillin-resistant Staphylococcus aureus (MRSA) induce tissue damage that recruits neutrophils, monocyte, and macrophages, leading to T cell exhaustion, fibrosis, vascular leak, epithelial cell depletion, and fatal organ damage. Neutrophils, monocytes, and macrophages recruited to pathogen-infected lungs, including SARS-CoV-2–infected lungs, express phosphatidylinositol 3-kinase gamma (PI3Kγ), a signaling protein that coordinates both granulocyte and monocyte trafficking to diseased tissues and immune-suppressive, profibrotic transcription in myeloid cells. PI3Kγ deletion and inhibition with the clinical PI3Kγ inhibitor eganelisib promoted survival in models of infectious diseases, including SARS-CoV-2 and MRSA, by suppressing inflammation, vascular leak, organ damage, and cytokine storm. These results demonstrate essential roles for PI3Kγ in inflammatory lung disease and support the potential use of PI3Kγ inhibitors to suppress inflammation in severe infectious diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Class Ib Phosphatidylinositol 3-KinaseCOVID-19InflammationSARS-CoV-2AnimalsHumansMiceCapillary PermeabilityCOVID-19 Drug TreatmentCytokine Release SyndromeLungMethicillin-Resistant Staphylococcus aureusMice, Inbred C57BLPhosphoinositide-3 Kinase InhibitorsStaphylococcal Infections

Substanzen

Class Ib Phosphatidylinositol 3-KinasePhosphoinositide-3 Kinase InhibitorsPik3cg protein, mouse

Autor:innen und Institutionen

  • Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA.
  • Department of Immunology, Scripps Research Institute, La Jolla, CA 92037, USA.
  • Department of Infectious Disease and Global Health, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, USA.
  • New England Regional Biosafety Laboratory, Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, USA.
  • Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, OR 97201, USA.
  • Department of Pathology, University of California, San Diego, La Jolla, CA 92093, USA.

ORCID-Profile: Ryan M Shepard, Anghesom Ghebremedhin, Isaraphorn Pratumchai, Sally R Robinson, Roman Sasik, Kathleen M Fisch, Jaroslav Zak, Hideya Seo, Alejandro D Campos, Denise Ann Dayao, Cesar Piedra-Mora, Soumita Das, Hana Russo, Xin Sun, Le Xu, Laura E Crotty Alexander, Jason M Duran, Mazen Odish, Victor Pretorius, Nell C Kirchberger, Shao-Ming Chin, Tami Von Schalscha, David Cheresh, Theodore A Martinot, Victor Nizet, Amanda J Martinot, Lisa M Coussens, John R Teijaro, Judith A Varner

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIDCR NIH HHS
  • NCATS NIH HHS
  • NIH HHS

Zitieren

APA

Shepard, R. M., Ghebremedhin, A., Pratumchai, I., Robinson, S. R., Betts, C., Hu, J., Sasik, R., Fisch, K. M., Zak, J., Chen, H., Paradise, M., Rivera, J., Amjad, M., Uchiyama, S., Seo, H., Campos, A. D., Dayao, D. A., Tzipori, S., Piedra-Mora, C., …, & Varner, J. A. (2024). PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections. Science Translational Medicine, 16(754). https://doi.org/10.1126/scitranslmed.adi6887

Vancouver

Shepard RM, Ghebremedhin A, Pratumchai I, Robinson SR, Betts C, Hu J, et al. PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections. Science Translational Medicine. 2024;16(754). doi:10.1126/scitranslmed.adi6887

BibTeX
@article{Shepard2024,
  author = {Shepard, Ryan M and Ghebremedhin, Anghesom and Pratumchai, Isaraphorn and Robinson, Sally R and Betts, Courtney and Hu, Jingjing and Sasik, Roman and Fisch, Kathleen M and Zak, Jaroslav and Chen, Hui and Paradise, Marc and Rivera, Jason and Amjad, Mohammad and Uchiyama, Satoshi and Seo, Hideya and Campos, Alejandro D and Dayao, Denise Ann and Tzipori, Saul and Piedra-Mora, Cesar and Das, Soumita and Hasteh, Farnaz and Russo, Hana and Sun, Xin and Xu, Le and Crotty Alexander, Laura E and Duran, Jason M and Odish, Mazen and Pretorius, Victor and Kirchberger, Nell C and Chin, Shao-Ming and Von Schalscha, Tami and Cheresh, David and Morrey, John D and Alargova, Rossitza and O'Connell, Brenda and Martinot, Theodore A and Patel, Sandip P and Nizet, Victor and Martinot, Amanda J and Coussens, Lisa M and Teijaro, John R and Varner, Judith A},
  title = {PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections},
  journal = {Science Translational Medicine},
  year = {2024},
  volume = {16},
  number = {754},
  doi = {10.1126/scitranslmed.adi6887}
}
Kostenlos starten →